Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519869 · ClinicalTrials.gov registry record · Phase 2
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
A Phase 2 study, sponsored by Rachel Miller.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01519869: Completed Phase 2 study, sponsored by Rachel Miller.
NCT01519869 is a Phase 2 study that has completed, run by Rachel Miller. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01519869, a Phase 2 study, has completed, sponsored by Rachel Miller.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increased quality of life in patients with International Federation of Gynecologic Oncology stages IIIC and IV ovarian, primary peritoneal, or fallopian tube cancer when compared to historical controls and to evaluate the hypothesis that cancer induced inflammation is a predictor of poor prognosis and response to therapy in this group of ovarian cancer patients.
Interventions
- DRUG neoadjuvant chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-03 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519869
The ClinicalTrials.gov registry entry for NCT01519869 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rachel Miller, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which neoadjuvant chemotherapy is the first listed.
NCT01519869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01519869 about?
NCT01519869 is a clinical study titled "Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma". This is a prospective study to evaluate the hypothesis that platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy is associated with improved maximal surgical cytoreduction rates, comparable survival, decreased morbidity, and increa...
What is the current status of trial NCT01519869?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2012-03. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT01519869?
The interventions under investigation include: neoadjuvant chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01519869?
This trial is sponsored by Rachel Miller, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.